Brief: Johnson & Johnson's Rybrevant Faspro™ (Amivantamab And Hyaluronidase-Lpuj) Receives U.S. FDA Priority Review As Potential First-In-Class Egfr- And Met-Targeted Subcutaneous Treatment For Advanced Head And Neck Cancer
30/07/2026 13:41
BRIEF-Johnson & Johnson's Rybrevant Faspro™ (Amivantamab And Hyaluronidase-Lpuj) Receives U.S. FDA Priority Review As Potential First-In-Class Egfr- And Met-Targeted Subcutaneous Treatment For Advanced Head And Neck Cancer July 30 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON'S RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) RECEIVES U.S. FDA PRIORITY REVIEW AS POTENTIAL FIRST-IN-CLASS EGFR- AND MET-TARGETED SUBCUTANEOUS TREATMENT FOR ADVANCED HEAD AND NECK CANCER
Source text: ID:nPn7ptQPQa
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Johnson & Johnson
See all newsEli Lilly hits record high as healthcare stocks rally
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived (updated)
Brief: Johnson & Johnson Announces New Data For Tremfya
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin